for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd

600332.SS

Latest Trade

31.34CNY

Change

-0.94(-2.91%)

Volume

9,878,561

Today's Range

31.21

 - 

32.14

52 Week Range

26.97

 - 

37.20

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
32.28
Open
32.06
Volume
9,878,561
3M AVG Volume
244.01
Today's High
32.14
Today's Low
31.21
52 Week High
37.20
52 Week Low
26.97
Shares Out (MIL)
1,625.79
Market Cap (MIL)
47,919.64
Forward P/E
14.39
Dividend (Yield %)
1.72

Next Event

Q4 2021 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Earnings Release

Latest Developments

更多

Guangzhou Baiyunshan Pharma s Q3 Net Profit Down 9.6% Y/Y

Guangzhou Baiyunshan Pharma's 6-Month Net Profit Up 41.8% Y/Y

Guangzhou Baiyunshan Says Unit Gets Regulatory Approval To Issue H-Shares

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd i is engaged in the pharmaceutical and healthcare industry. The Company's segments are Great Southern TCM, Great Commerce, Great Health and Great Medical Care. The Company's Great South TCM includes research, development, manufacturing and sales for Chinese and western medicine, chemical raw medicine, natural drug, biological medicine and intermediates of chemical raw medicine. The Company's Great Health segment includes the research, development, manufacturing and sales of beverages, foods, health products and other products. The Company's Great Commerce segment includes wholesale, retail, import and export for western medicine, Chinese medicine and medical apparatus and instruments. The Great Medical segment is engaged in medical services, traditional Chinese medicine health preservation, modern pension and medical equipment industry.

Industry

Biotechnology & Drugs

Contact Info

No. 45 Shamian North Street

Liwan District

GUANGZHOU, GNG

510130

China

+86.20.66281217

http://www.gybys.com.cn/

Executive Leadership

Chuyuan Li

Chairman of the Board, Executive Director

Ning Cheng

Vice Chairman of the Board, Executive Director

Jun Yang

Vice Chairman of the Board, Executive Director

Hong Li

General Manager, Executive Director

Haiwen Huang

Deputy General Manager

Key Stats

2.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

42.2K

2019

65.0K

2020

61.7K

2021(E)

68.7K
EPS (CNY)

2018

2.120

2019

1.961

2020

1.793

2021(E)

2.179
Price To Earnings (TTM)
14.28
Price To Sales (TTM)
0.70
Price To Book (MRQ)
1.78
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
46.55
LT Debt To Equity (MRQ)
4.46
Return on Investment (TTM)
12.76
Return on Equity (TTM)
6.14

Latest News

Latest News

《股市简讯》中国白云山A股挫3.5%至两个月新低,三季度净利下滑约一成

* 白云山从事制药和保健行业。该公司的业务分部包括:大南药分部、大健康分部、大商业分部和大医疗分部。其中大南药分部从事研究、开发、制造和销售中西成药、化学原料药等,而大健康分部从事研究、开发、制造和销售饮料、食品、保健品等产品。(完)

《股市简讯》中国博瑞医药涨逾8%创三周新高,二季度营收净利创新高

* 中国博瑞医药周三一度涨8.6%,创三周以来新高,后有所回落;上日公布业绩显示,上半年净利同比增长45%,且二季度营收和净利均创单季新高。

BRIEF-中国制药公司白云山上半年净利同比增长42%,受益于市场需求回升

* 随着国内新冠疫情的逐步缓和,市场需求回升,公司销售及主营业务利润增长。其中阿莫西林系列等产品销售收入同比实现较大的增长。

《股市简讯》中国长春高新由跌转涨最高涨近4%,上半年净利润同比劲增近五成

* 中国生长激素制造企业--长春高新周一早盘低开但随后转涨,盘中最高一度涨3.77%,创8月3日以来新高。上周五,长春高新发布中报显示,上半年实现净利润19.23亿元人民币,同比增长46.85%。

《股市简讯》白云山股价大涨,有报导称其产品对新冠病毒有效

港股白云山周五盘中一度大涨15.1%,触及22.1港元。有媒体报导称,白云山旗下一产品对新冠病毒有效。 白云山有望创下2018年10月30日以来单日最大涨幅。 广州日报报导称,中国抗疫专家锺南山称,白云山复方板蓝根颗粒对新冠病毒有效。 A股白云山亦劲升10%。(完) (编译 蔡美珍;审校 张涛)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up